OBJECTIVES: To assess the presentation and diagnosis of, and treatment options for, multilocular cystic renal cell carcinoma (MCRCC). MCRCC is a rare entity and the true incidence and biologic behavior of MCRCC are not well known. METHODS: We reviewed the pathology files at the Queen Elizabeth II Health Sciences Centre for a 9-year period (1991 to 2000). All cases of RCC with a cystic component were identified. The clinical features, radiologic features, surgical procedure, pathologic features, and follow-up outcomes of the MCRCC cases were studied. RESULTS: We identified 12 cases of MCRCC comprising 3.1% of the RCC cases. The tumor was incidentally found in 67% of the cases. Ultrasonography was found to be a useful screening test, but computed tomography is the imaging study of choice to identify malignant features. Magnetic resonance imaging can be used in equivocal cases. For treatment, radical nephrectomy was done in 58% and partial nephrectomy in 33%. The mean tumor size was 3.4 cm. The mean solid component of the tumor was 9.5%. The mean tumor grade was 1.1. None of the 10 patients (83%) available for follow-up showed any evidence of recurrence. They were followed up for an average of 42.5 months. CONCLUSIONS: MCRCC is an uncommon subtype (3%) of RCC. The term MCRCC should be used exclusively to identify cystic RCC with a small volume (25% or less) of neoplastic clear cells in the cyst walls. The benign clinical course of these lesions suggests that patients may benefit from nephron-sparing surgery.
OBJECTIVES: To assess the presentation and diagnosis of, and treatment options for, multilocular cystic renal cell carcinoma (MCRCC). MCRCC is a rare entity and the true incidence and biologic behavior of MCRCC are not well known. METHODS: We reviewed the pathology files at the Queen Elizabeth II Health Sciences Centre for a 9-year period (1991 to 2000). All cases of RCC with a cystic component were identified. The clinical features, radiologic features, surgical procedure, pathologic features, and follow-up outcomes of the MCRCC cases were studied. RESULTS: We identified 12 cases of MCRCC comprising 3.1% of the RCC cases. The tumor was incidentally found in 67% of the cases. Ultrasonography was found to be a useful screening test, but computed tomography is the imaging study of choice to identify malignant features. Magnetic resonance imaging can be used in equivocal cases. For treatment, radical nephrectomy was done in 58% and partial nephrectomy in 33%. The mean tumor size was 3.4 cm. The mean solid component of the tumor was 9.5%. The mean tumor grade was 1.1. None of the 10 patients (83%) available for follow-up showed any evidence of recurrence. They were followed up for an average of 42.5 months. CONCLUSIONS: MCRCC is an uncommon subtype (3%) of RCC. The term MCRCC should be used exclusively to identify cystic RCC with a small volume (25% or less) of neoplastic clear cells in the cyst walls. The benign clinical course of these lesions suggests that patients may benefit from nephron-sparing surgery.
Authors: Brian R Winters; John L Gore; Sarah K Holt; Jonathan D Harper; Daniel W Lin; Jonathan L Wright Journal: Urol Oncol Date: 2015-08-28 Impact factor: 3.498
Authors: Milan Hora; Ondrej Hes; Michal Michal; Ludmila Boudová; Zdenek Chudácek; Boris Kreuzberg; Jirí Klecka Journal: Int Urol Nephrol Date: 2005 Impact factor: 2.370
Authors: Patrick O Richard; Philippe D Violette; Michael A S Jewett; Frederic Pouliot; Michael Leveridge; Alan So; Thomas F Whelan; Ricardo Rendon; Antonio Finelli Journal: Can Urol Assoc J Date: 2017-03-16 Impact factor: 1.862
Authors: Maria Tretiakova; Vikas Mehta; Masha Kocherginsky; Agata Minor; Steven S Shen; Sahussapont Joseph Sirintrapun; Jorge L Yao; Isabel Alvarado-Cabrero; Tatjana Antic; Scott E Eggener; Maria M Picken; Gladell P Paner Journal: Virchows Arch Date: 2018-05-17 Impact factor: 4.064
Authors: Jindong Chen; Kunihiko Futami; David Petillo; Jun Peng; Pengfei Wang; Jared Knol; Yan Li; Sok-Kean Khoo; Dan Huang; Chao-Nan Qian; Ping Zhao; Karl Dykema; Karl Dykyma; Racheal Zhang; Brian Cao; Ximing J Yang; Kyle Furge; Bart O Williams; Bin Tean Teh Journal: PLoS One Date: 2008-10-30 Impact factor: 3.240